Clinical Trial

QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy, safety and immunogenicity of QCL7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-24.
Trial Details
NCT Number NCT07441317
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Primary Hypercholesterolemia or Mixed Hyperlipidemia
Enrollment 780 participants
Start Date 2026-03
Primary Completion 2027-12 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-04